Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Stage of Development | 8 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Therapy Area | 9 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Indication | 10 | 2 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Companies | 14 | 2 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Universities/Institutes | 16 | 2 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Therapeutics Assessment | 18 | 5 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Companies Involved in Therapeutics Development | 23 | 4 |
| Advenchen Laboratories, LLC | 23 | 1 |
| Athenex, Inc. | 24 | 1 |
| Basilea Pharmaceutica AG | 25 | 1 |
| Pfizer Inc. | 26 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Drug Profiles | 27 | 20 |
| apatinib Drug Profile | 27 | 3 |
| bosutinib Drug Profile | 30 | 5 |
| CCT-196969 Drug Profile | 35 | 1 |
| CCT-241161 Drug Profile | 36 | 1 |
| eCF-506 Drug Profile | 37 | 1 |
| KX-01 Drug Profile | 38 | 2 |
| KX-02 Drug Profile | 40 | 2 |
| PP-1 Drug Profile | 42 | 1 |
| Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology Drug Profile | 43 | 1 |
| Small molecules to Inhibit Src Kinase for Oncology Drug Profile | 44 | 1 |
| Small Molecules to Inhibit Src Tyrosine Kinase for Colon Cancer Drug Profile | 45 | 1 |
| UM-164 Drug Profile | 46 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Dormant Projects | 47 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Discontinued Products | 48 | 1 |
| Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Featured News &Press Releases | 49 | 10 |
| Jun 08, 2016: New compound shows potential for triple-negative breast cancer | 49 | 1 |
| May 23, 2016: Breast cancer drug discovery offers hope of new treatments | 50 | 1 |
| Sep 15, 2015: Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia | 50 | 1 |
| Feb 18, 2015: Particle Sciences Manufactures Clinical Supplies for Kinex's Glioblastoma Therapeutic | 51 | 1 |
| Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study | 51 | 1 |
| Dec 24, 2014: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study | 52 | 1 |
| Dec 09, 2014: Pfizer Demonstrates New Data On BOSULIF at ASH 2014 | 53 | 1 |
| Aug 11, 2014: Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia | 53 | 1 |
| Jul 24, 2014: Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) | 54 | 1 |
| Mar 30, 2014: Atlantic Research Group Client Kinex Pharmaceuticals Initiate Phase I Glioblastoma trial | 55 | 1 |
| Jan 09, 2014: Avillion Partners with Pfizer to Co-develop BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia | 55 | 1 |
| Dec 04, 2013: Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas | 56 | 1 |
| Jul 16, 2013: NICE consults on a new treatment for chronic myeloid leukaemia | 56 | 1 |
| Jun 04, 2013: Kinex Pharma Receives IND Approval From FDA For KX02 Clinical Trials In Brain Tumor Patients | 57 | 1 |
| Mar 28, 2013: Pfizer s Bosulif Receives Conditional Marketing Authorization From European Commission | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |